DrugPatentWatch Database Preview
Abbvie Company Profile
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
There are eighty-one US patents protecting ABBVIE drugs.
There are one thousand two hundred and eighty-four patent family members on ABBVIE drugs in sixty-six countries and one hundred and thirteen supplementary protection certificates in fourteen countries.
Summary for Abbvie
| International Patents: | 1284 |
| US Patents: | 81 |
| Tradenames: | 77 |
| Ingredients: | 64 |
| NDAs: | 89 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | NITROPRESS | sodium nitroprusside | INJECTABLE;INJECTION | 018450-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Abbvie | TARKA | trandolapril; verapamil hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 020591-003 | Oct 22, 1996 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Abbvie | TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224-002 | Dec 15, 2008 | AB | RX | Yes | Yes | 7,259,186 | ➤ Sign Up | Y | ➤ Sign Up | ||
| Abbvie | KALETRA | lopinavir; ritonavir | SOLUTION;ORAL | 021251-001 | Sep 15, 2000 | AA | RX | Yes | Yes | 6,911,214*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | TRICOR | fenofibrate | TABLET;ORAL | 021656-001 | Nov 5, 2004 | 5,145,684 | ➤ Sign Up |
| Abbvie | NIASPAN TITRATION STARTER PACK | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-005 | Jul 28, 1997 | 6,406,715 | ➤ Sign Up |
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020011-001 | Oct 22, 1990 | 5,480,656 | ➤ Sign Up |
| Abbvie | NIASPAN TITRATION STARTER PACK | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-005 | Jul 28, 1997 | 6,080,428 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
| ➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
| ➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
| ➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
| ➤ Subscribe | Gel Metered-dose Pump | 1% | ➤ Subscribe | 2008-12-19 |
| ➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
| ➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
| ➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
| ➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
| ➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
| ➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Gel | 1.62% | ➤ Subscribe | 2012-04-06 |
| ➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Gel | 1.62% (1.25 g and 2.5 g packets) | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
| ➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
Non-Orange Book US Patents for Abbvie
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,452,194 | Methods for treating HCV | ➤ Sign Up |
| 6,558,679 | Container for an inhalation anesthetic | ➤ Sign Up |
| 8,193,367 | Polymorph of a pharmaceutical | ➤ Sign Up |
| 6,596,317 | Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Abbvie Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| China | 1535168 | ➤ Sign Up |
| Australia | 2001286995 | ➤ Sign Up |
| Hungary | 0000808 | ➤ Sign Up |
| New Zealand | 567056 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Abbvie Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C/GB95/010 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| C0016 | France | ➤ Sign Up | PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119 |
| C/GB06/021 | United Kingdom | ➤ Sign Up | PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201 |
| 0901 | Netherlands | ➤ Sign Up | PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
